Levetiracetam Injection
Product Images NDC 44567-502

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 44567-502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wg Critical Care, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

250 mg Carton Label (Image 01)

Levetiracetam 5 mg/mL injection in 0.82% sodium chloride, presented as 250 mg/50 mL single-dose bags. The label specifies intravenous infusion use only, with a quantity of 10 bags per package. Manufactured by WG Critical Care, LLC.*

FDA Label Image

1000 mg Carton Label (Image 02)

Levetiracetam 1000 mg/100 mL (10 mg/mL) intravenous injection in 0.75% sodium chloride solution. The label indicates a package of 10 x 100 mL single-dose bags. The product is labeled by WG Critical Care, LLC and is designated for intravenous infusion only.*

FDA Label Image

1500 mg Carton Label (Image 03)

Levetiracetam injection in 0.54% Sodium Chloride, 1500 mg per 100 mL (15 mg/mL) strength, in a 10 x 100 mL single-dose bag. The label indicates it is for intravenous infusion only, prescription use, and is manufactured by WG Critical Care, LLC.*

FDA Label Image

Levetiracetam Structural Formula (Image 04)

Chemical structure of the active ingredient Levetiracetam. The diagram shows the molecular framework including a pyrrolidone ring and attached functional groups representing Levetiracetam's chemical composition.*

FDA Label Image

500 mg Carton Label (Image 05)

Levetiracetam 5 mg/mL Injection in 0.82% Sodium Chloride, 500 mg/100 mL, intravenous infusion solution. Package label from WG Critical Care, LLC showing 10 x 100 mL single-dose bags, Rx only.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Image 06)

A bar chart displaying the percentage of patients across three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The chart shows patient percentages of 6.3% for placebo, 20.8% for levetiracetam 1000 mg/day, and 35.2% for levetiracetam 2000 mg/day, with statistically significant differences marked for the levetiracetam groups versus placebo.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Image 07)

A bar chart comparing the percentage of patients for Placebo (N=104) versus Levetiracetam 3000 mg/day (N=180). The vertical axis shows the percentage of patients, with Placebo at 14.4% and Levetiracetam at 39.4%, indicating a statistically significant difference between the two groups.*

FDA Label Image

Figure 4: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (Image 08)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents the percentage of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, while the Levetiracetam group (N=79) shows 72.2%, with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Figure 1 (Image 09)

A bar graph comparing percentages of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis represents the percentage of patients, with the Levetiracetam 3000 mg/day group showing the highest percentage near 40%, followed by the 1000 mg/day group near 37%, and Placebo at about 7.4%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.